Sangamo BioSciences | SGMO - Current Assets


Sangamo BioSciences reported $49.89M in Current Assets for its fiscal quarter ending in June of 2025.





Current Assets Change Date
Alaunos Therapeutics USD 666K 304K Jun/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
Amgen USD 34.36B 598M Sep/2026
Bayer EUR 39.6B 5.96B Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Cipla INR 250.61B 9.14B Sep/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 129.41M 7.88M Jun/2026
CSL USD 11.85B 1000K Dec/2025
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Grifols EUR 5.96B 316.31M Dec/2025
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
J&J USD 56.35B 3.42B Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Merck USD 38.94B 2.26B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Omeros USD 69.65M 26.53M Jun/2025
Pfizer USD 45.01B 3.65B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 33.21B 1.68B Sep/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Tectonic Therapeutic USD 231.1M 8.79M Jun/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026